NASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $7.72 +0.49 (+6.78%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$7.64 -0.08 (-0.97%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arvinas Stock (NASDAQ:ARVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arvinas alerts:Sign Up Key Stats Today's Range$6.80▼$8.0050-Day Range$6.19▼$18.2852-Week Range$5.94▼$37.38Volume8.59 million shsAverage Volume1.25 million shsMarket Capitalization$530.92 millionP/E RatioN/ADividend YieldN/APrice Target$25.82Consensus RatingModerate Buy Company OverviewArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More… Arvinas Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreARVN MarketRank™: Arvinas scored higher than 66% of companies evaluated by MarketBeat, and ranked 242nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arvinas' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.86% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arvinas has recently increased by 20.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.86% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arvinas has recently increased by 20.97%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.22 News SentimentArvinas has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Arvinas this week, compared to 6 articles on an average week.Search InterestOnly 12 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $769,402.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Stock News HeadlinesJefferies Downgrades Arvinas (ARVN)May 2 at 4:10 PM | msn.comArvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets ChallengesMay 2 at 11:09 AM | marketwatch.comWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.May 3, 2025 | Stansberry Research (Ad)Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...May 2 at 11:09 AM | finance.yahoo.comHere are 1 Main Capital Partners’ Views on Arvinas (ARVN)May 2 at 11:09 AM | finance.yahoo.comArvinas, Inc. (ARVN) Q1 2025 Earnings Call TranscriptMay 1 at 10:06 PM | seekingalpha.comBREAKING: Block & Leviton Investigating Arvinas, Inc. (ARVN) For Securities Fraud After Shares Fall Over 20%; Investors Encouraged to Contact the Firm to Potentially Recover LossesMay 1 at 5:44 PM | globenewswire.comArvinas stock tumbles following workforce reduction and trial removalsMay 1 at 1:45 PM | investing.comSee More Headlines ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $19.17 at the beginning of 2025. Since then, ARVN stock has decreased by 59.7% and is now trading at $7.72. View the best growth stocks for 2025 here. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) issued its earnings results on Thursday, May, 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. The company's revenue for the quarter was up 646.2% compared to the same quarter last year. Read the conference call transcript. When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. Who are Arvinas' major shareholders? Top institutional investors of Arvinas include Bank of New York Mellon Corp (0.25%), Banque Pictet & Cie SA (0.14%), Rhumbline Advisers (0.13%) and Assenagon Asset Management S.A. (0.12%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/01/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARVN CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees420Year FoundedN/APrice Target and Rating Average Stock Price Target$25.82 High Stock Price Target$69.00 Low Stock Price Target$8.00 Potential Upside/Downside+234.5%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,900,000.00 Net Margins-75.51% Pretax Margin-75.29% Return on Equity-33.75% Return on Assets-16.75% Debt Debt-to-Equity RatioN/A Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual Sales$263.40 million Price / Sales2.02 Cash FlowN/A Price / Cash FlowN/A Book Value$8.17 per share Price / Book0.94Miscellaneous Outstanding Shares68,772,000Free Float65,175,000Market Cap$530.92 million OptionableOptionable Beta2.30 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ARVN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.